Arcadia Biosciences Inc. CEO Matt Plavan tells Proactive the group posted fourth-quarter results on Wednesday that saw its 2020 revenue increase six-fold to $8M from 2019, despite the impact of the coronavirus pandemic. Plavan says strategic transactions allowed to group to reduce its loss, in addition to financial raises putting it the group “in really good stead.” He adds that the group is expecting “meaningful revenue traction in 2021 as well.”
